Literature DB >> 3144365

Anticoagulants in venous thromboembolism.

A Fennerty1, I A Campbell, P A Routledge.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1988        PMID： 3144365      PMCID： PMC1834928          DOI： 10.1136/bmj.297.6659.1285

Source DB:  PubMed          Journal:  BMJ        ISSN： 0959-8138


× No keyword cloud information.
  34 in total

1.  A prospective study of the value of monitoring heparin treatment with the activated partial thromboplastin time.

Authors:  D Basu; A Gallus; J Hirsh; J Cade
Journal:  N Engl J Med       Date:  1972-08-17       Impact factor: 91.245

2.  Audit of control of heparin treatment.

Authors:  A G Fennerty; P Thomas; G Backhouse; P Bentley; I A Campbell; P A Routledge
Journal:  Br Med J (Clin Res Ed)       Date:  1985-01-05

3.  Flexible induction dose regimen for warfarin and prediction of maintenance dose.

Authors:  A Fennerty; J Dolben; P Thomas; G Backhouse; D P Bentley; I A Campbell; P A Routledge
Journal:  Br Med J (Clin Res Ed)       Date:  1984-04-28

4.  Difficulties in the treatment of acute pulmonary embolism.

Authors:  R Hall
Journal:  Thorax       Date:  1985-10       Impact factor: 9.139

5.  Drug-related deaths among medical inpatients.

Authors:  J Porter; H Jick
Journal:  JAMA       Date:  1977-02-28       Impact factor: 56.272

6.  Randomized prospective trial of continuous vs intermittent heparin therapy.

Authors:  R L Glazier; E B Crowell
Journal:  JAMA       Date:  1976-09-20       Impact factor: 56.272

7.  Heparin therapy in venous thromboembolism.

Authors:  J E Wilson; L J Bynum; R W Parkey
Journal:  Am J Med       Date:  1981-04       Impact factor: 4.965

8.  Different intensities of oral anticoagulant therapy in the treatment of proximal-vein thrombosis.

Authors:  R Hull; J Hirsh; R Jay; C Carter; C England; M Gent; A G Turpie; D McLoughlin; P Dodd; M Thomas; G Raskob; P Ockelford
Journal:  N Engl J Med       Date:  1982-12-30       Impact factor: 91.245

9.  Impact of venography on the diagnosis and management of deep vein thrombosis.

Authors:  L E Ramsay
Journal:  Br Med J (Clin Res Ed)       Date:  1983-02-26

10.  Acute pulmonary embolism treated with tissue plasminogen activator.

Authors:  S Z Goldhaber; D E Vaughan; J E Markis; A P Selwyn; M F Meyerovitz; J Loscalzo; D S Kim; C M Kessler; D L Dawley; G V Sharma
Journal:  Lancet       Date:  1986-10-18       Impact factor: 79.321
View more
  13 in total

1.  After a first episode of venous thromboembolism.

Authors:  C N Chesterman
Journal:  BMJ       Date:  1995-09-16

2.  Audit of anticoagulant therapy.

Authors:  P E Rose
Journal:  J Clin Pathol       Date:  1996-01       Impact factor: 3.411

3.  Control of warfarin therapy.

Authors:  A Fennerty; P A Routledge
Journal:  Postgrad Med J       Date:  1990-02       Impact factor: 2.401

4.  Non-biological factors in day to day variation of heparin requirements.

Authors:  A G Fennerty; M N Levine
Journal:  BMJ       Date:  1989-10-21

5.  Anticoagulants in venous thromboembolism.

Authors:  M D Stringer; N Wilson; V V Kakkar
Journal:  BMJ       Date:  1989-01-21

Review 6.  Control of warfarin therapy.

Authors:  D K Scott
Journal:  Postgrad Med J       Date:  1989-09       Impact factor: 2.401

7.  Clinical presentation and investigation of patients proceeding to isotope lung scanning for suspected pulmonary embolism.

Authors:  A G Fennerty; H G Shetty; D Paton; G Roberts; P A Routledge; I A Campbell
Journal:  Postgrad Med J       Date:  1990-04       Impact factor: 2.401

8.  A new regimen for starting warfarin therapy in out-patients.

Authors:  A Oates; P R Jackson; C A Austin; K S Channer
Journal:  Br J Clin Pharmacol       Date:  1998-08       Impact factor: 4.335

9.  Anticoagulation for three versus six months in patients with deep vein thrombosis or pulmonary embolism, or both: randomised trial.

Authors:  I A Campbell; D P Bentley; R J Prescott; P A Routledge; H G M Shetty; I J Williamson
Journal:  BMJ       Date:  2007-02-08

Review 10.  Adverse drug reactions. An overview of special considerations in the management of the elderly patient.

Authors:  L A Brawn; C M Castleden
Journal:  Drug Saf       Date:  1990 Nov-Dec       Impact factor: 5.606
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.